Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
Inquirer on MSN2d
Controlled drug Ketamine a lifeline for patients with severe depression in S’poreKetamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Policing minister Dame Diana Johnson will write to the Advisory Council on the Misuse of Drugs asking whether its classification should be changed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback